MedTrace Logo

A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis B

NCT07771140 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2026-08-18

No results posted yet for this study

Summary

To evaluate the safety, efficacy, pharmacokinetics and immunogenicity of single and multiple doses of HECN30227 Injection in healthy volunteers and patients with chronic hepatitis B

Conditions

  • HBV Infection

Interventions

DRUG

HECN30227 injection(SAD)

single subcutaneous administrations

DRUG

Placebo(MAD)

0.9% Sodium Chloride Injection

DRUG

Placebo(SAD)

0.9% Sodium Chloride Injection

DRUG

HECN30227 injection (MAD)

multiple subcutaneous administrations

Sponsors & Collaborators

  • Sunshine Lake Pharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-02
Primary Completion
2027-04-11
Completion
2027-04-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07771140 on ClinicalTrials.gov